Open Label Study of the Anti Insulin-like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibody, AVE1642, as Single Agent (Dose Escalation, Part 1) and in Combination With Velcade (Combination, Part 2) in Patients With Recurrent, Refractory Multiple Myeloma (MM)

Trial Profile

Open Label Study of the Anti Insulin-like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibody, AVE1642, as Single Agent (Dose Escalation, Part 1) and in Combination With Velcade (Combination, Part 2) in Patients With Recurrent, Refractory Multiple Myeloma (MM)

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs AVE 1642 (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top